English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/73457
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Deep brain stimulation of the subcallosal cingulate gyrus: Further evidence in treatment-resistant major depression

AuthorsPuigdemont, Dolors; Pérez-Egea, Rosario; Portella, Maria J.; Molet, Joan; Diego-Adeliño, Javier de; Gironell, Alexandre; Radua, Joaquim; Gómez-Anson, Beatriz; Rodríguez, Rodrigo; Serra, Maria ; Quintana, Cristian de; Artigas, Francesc ; Álvarez, Enric; Pérez, Víctor
Issue Date2012
PublisherCambridge University Press
CitationInternational Journal of Neuropsychopharmacology 15(1): 121-133 (2012)
AbstractDeep brain stimulation (DBS) is currently tested as an experimental therapy for patients with treatment-resistant depression (TRD). Here we report on the short-and long-term (1 yr) clinical outcomes and tolerance of DBS in eight TRD patients. Electrodes were implanted bilaterally in the subgenual cingulate gyrus (SCG; Broadman areas 24-25), and stimulated at 135 Hz (90-μs pulsewidth). Voltage and active electrode contacts were adjusted to maximize short-term responses. Clinical assessments included the 17-item Hamilton Depression Rating Scale (HAMD17; primary measure), the Montgomery-Ãsberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) Scale. In the first week after surgery, response and remission (HAMD ≤7) rates were, respectively 87.5% and 50%. These early responses were followed by an overall worsening, with a response and remission rates of 37.5% (3/8) at 1 month. From then onwards, patients showed a progressive improvement, with response and remission rates of 87.5% and 37.5%, respectively, at 6 months. The corresponding figures at 1 yr were 62.5% and 50%, respectively. Clinical effects were seen in all HAMD subscales without a significant incidence of side-effects. Surgical procedure and post-operative period were well-tolerated for all patients. This is the second independent study on the use of DBS of the SCG to treat chronic depression resistant to current therapeutic strategies. DBS fully remitted 50% of the patients at 1 yr, supporting its validity as a new therapeutic strategy for TRD. © 2011 CINP.
Publisher version (URL)http://dx.doi.org/10.1017/S1461145711001088
Identifiersdoi: 10.1017/S1461145711001088
issn: 1461-1457
e-issn: 1469-5111
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
345671.pdf205,82 kBUnknownView/Open
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.